Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma

P. N. Mainwaring, H. Atkinson, J. Chang, J. Moore, B. W. Hancock, P. J. Guillou, R. Oskam, M. E. Gore

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


An open, multicentre non-randomised study was performed to evaluate the activity and toxicity of combination chemoimmunotherapy, consisting of cisplatin, interleukin-2 and interferon-α, in metastatic malignant melanoma. Between March 1992 and September 1993, 28 patients with pathologically proven metastatic malignant melanoma, bidimensionally measurable disease and an Eastern Co-operative Oncology Group score χ1 were treated with the combination chemoimmunotherapy. The regimen consisted of cisplatin (100 mg/m2 on day 0), interleukin-2 (Proleukin, Chiron, Middlesex, U.K.) 18 x 106 IU/m2/d continuous intravenous infusion on days 3-7 and 17-22, with interferon-α (Roferon-A, Roche, Hertfordshire, U.K.) 9 x 106U/d subcutaneously on days 3, 5, 7, 17, 19, 21 during the interleukin-2 infusions. The treatment cycle lasted 28 days. Among 27 assessable patients, 5 patients achieved partial responses, for an overall response rate of 18% (95% CI 6-37%). Median progression-free survival was 44 days (range 8-279) and median overall survival was 264 days (range 41-1432). Differential responses were noted in 41% of patients and responses were more frequent in non-visceral disease (skin, lymph node and soft tissue disease) (P = 0.04). These results indicate that differential responses to chemoimmunotherapy are common in patients with metastatic melanoma. This may account for the broad range of response rates reported in the literature.

Original languageEnglish (US)
Pages (from-to)1388-1392
Number of pages5
JournalEuropean Journal of Cancer Part A
Issue number9
StatePublished - Aug 1997


  • Chemoimmunotherapy
  • Cisplatin
  • Differential responses
  • Interferon- α
  • Interleukin-2
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma'. Together they form a unique fingerprint.

Cite this